The Japanese clinical practice guidelines for NSCLC recommend various therapies as a treatment option for second- and later-line therapy, including RAM + DTX therapy, pemetrexed monotherapy [21], S-1 monotherapy [22], nanoparticle albumin-bound paclitaxel monotherapy [23] and others. Here, ALB is linked to non-small cell lung carcinoma.